Catalyst Pharma (NASDAQ: CPRX) outlines JPM Healthcare presentation

Rhea-AI Filing Summary

Catalyst Pharmaceuticals, Inc. reported that it will present at the 44th Annual JP Morgan Healthcare Conference on January 12, 2026. The company has made its conference slide presentation available as Exhibit 99.1 to this report and incorporates it by reference. The disclosure is furnished under Regulation FD, meaning it is not treated as filed for liability purposes or automatically included in other securities law filings. The company also highlights that the report and presentation contain forward-looking statements and directs readers to its Form 10-K for the year ended December 31, 2024 and subsequent SEC reports for a discussion of risks that could cause actual results to differ.

NASDAQ false 0001369568 0001369568 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): January 12, 2026

CATALYST PHARMACEUTICALS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Delaware		001-33057		76-0837053
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

355 Alhambra Circle
Suite 801
Coral Gables, Florida				33134
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (305) 420-3200

Not Applicable

Former Name or Former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Name of Exchange on Which Registered		Ticker Symbol
Common Stock, par value $0.001 per share		NASDAQ Capital Market		CPRX

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On January 12, 2026, the Company will be presenting at the 44^th Annual JP Morgan Healthcare conference. The presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, is furnished pursuant to Exhibit 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the limitations of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company’s submission of this Form 8-K shall not be deemed as an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Forward-Looking Statements

This Form 8-K and the presentation contain forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect the Company. Copies of the Company’s filings with the SEC are available from the SEC, may be found on the Company’s website, or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein or therein, which speak only as of this date.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1		Presentation, dated January 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceuticals, Inc.
By:		/s/ Michael W. Kalb
		Michael W. Kalb
		Executive Vice President and Chief Financial Officer

Dated: January 12, 2026

3

FAQ

What did Catalyst Pharmaceuticals (CPRX) disclose in its latest report?

Catalyst Pharmaceuticals disclosed that it will present at the 44th Annual JP Morgan Healthcare Conference on January 12, 2026 and attached its presentation as Exhibit 99.1, incorporating it by reference.

What is the event Catalyst Pharmaceuticals (CPRX) is participating in?

The company will be presenting at the 44th Annual JP Morgan Healthcare Conference on January 12, 2026.

How is the Catalyst Pharmaceuticals conference information treated under securities laws?

The conference information in Item 7.01, including Exhibit 99.1, is furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Does Catalyst Pharmaceuticals provide any forward-looking statements in this disclosure?

Yes. The company states that this report and the presentation contain forward-looking statements, which involve risks and uncertainties that could cause actual results to differ materially from forecasts.

Where can investors find more information on Catalyst Pharmaceuticals (CPRX) risks?

The company refers investors to its Annual Report on Form 10-K for the year ended December 31, 2024 and its subsequent filings with the SEC for a detailed description of risk factors.

Who signed the report for Catalyst Pharmaceuticals?

The report was signed on behalf of Catalyst Pharmaceuticals, Inc. by Michael W. Kalb, Executive Vice President and Chief Financial Officer.